<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82570">
  <stage>Registered</stage>
  <submitdate>28/01/2008</submitdate>
  <approvaldate>31/01/2008</approvaldate>
  <actrnumber>ACTRN12608000061336</actrnumber>
  <trial_identification>
    <studytitle>ANTS Trial (Australian Neoadjuvant Therapy Study for Non-small Cell Lung Cancer)</studytitle>
    <scientifictitle>A randomised phase II study comparing cisplatin and docetaxel with or without cetuximab given as neoadjuvant therapy in patients with stage II and IIIA resectable non-small cell lung cancer.</scientifictitle>
    <utrn />
    <trialacronym>ANTS (Australian Neoadjuvant Therapy Study)</trialacronym>
    <secondaryid>Trial Number: ALTG 04/008</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-small Cell Lung Cancer (NSCLC)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Standard chemotherapy (cisplatin 75mg/m2 i.v. and docetaxel 75mg/m2 i.v., 3-weekly for 3 cycles) plus cetuximab 400mg/m2 i.v., then 250mg/m2 i.v. weekly, followed by surgery</interventions>
    <comparator>Standard chemotherapy (cisplatin 75mg/m2 i.v. and docetaxel 75mg/m2 i.v., 3-weekly for 3 cycles), followed by surgery</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To estimate the pathologic response rate of chemotherapy plus cetuximab and relate this rate to that for chemotherapy alone.</outcome>
      <timepoint>Following 3 cycles of chemotherapy (approximately 9 weeks)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare response as assessed by Computed Tomography (CT) scanning</outcome>
      <timepoint>Following 3 cycles of chemotherapy (approximately 9 weeks)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) Histological diagnosis of NSCLC
2) Adequate baseline histological specimen available
3) Measurable primary tumour
4) Stage II or IIIA
5) Considered to be surgically resectable by thoracic surgeon
6) No prior therapy for NSCLC
7) Performance Status 0-1
8) Peripheral neuropathy no worse than grade I
9) Adequate organ function including lung, hepatic, renal and haematological function
10) Written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) No prior malignancy within 5 years
2) No other concurrent investigational drug
3) No active infection
4) No pregnancy or breast feeding 
5) No serious concomitant medical or psychiatric disorders
6) No significant cardiovascular disease
7) No concurrent systemic corticosteroid (prednisolone &gt;10 mg/day, or equivalent)
8) No history of severe hypersensitivity reactions to polysorbate 80 or any of the study medications.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Eligible patients will be registered and randomised via the Coordinating Trial Centre at Peter MacCallum Cancer Centre. Randomisation will be 2:1 experimental vs standard arms.</concealment>
    <sequence>Minimisation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures>Tumour and normal tissue specimens will be collected to investigate the molecular effects of chemotherapy and of cetuximab</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/02/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3084</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress>Studley Rd, Heidelberg, VIC 3084</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Sanofi-Aventis</fundingname>
      <fundingaddress>12-24 Talavera Rd
Macquarie Park
NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Merck Serono</fundingname>
      <fundingaddress>U3 / 25 Frenchs Forest
Frenchs Forest
NSW 2086</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council</fundingname>
      <fundingaddress>GPO Box 1421
Canberra
ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of the study is to estimate the benefit of adding cetuximab to standard chemotherapy, administered prior to surgery. Cetuximab inhibits the Epidermal Growth Factor receptor. Additional objectives are to examine the relationships between various measures of tumour shrinkage and various molecular analyses of normal and cancer tissues. This may provide information on how cetuximab works, and which patients benefit most from the drug, as well as further information on the effects of chemotherapy.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Research Ethics Committee, Austin Health</ethicname>
      <ethicaddress>Studley Rd, Heidelberg, VIC 3084</ethicaddress>
      <ethicapprovaldate>1/04/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof Paul Mitchell</name>
      <address>Austin Health, Studley Rd, Heidelberg, VIC 3084</address>
      <phone>+61 3 9496 3546</phone>
      <fax>+61 3 9496 3379</fax>
      <email>paul.mitchell@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Bev McClur</name>
      <address>CBCT, Pater MacCallum Cancer Centre, St Andrews Place, East Melbourne, VIC 3002</address>
      <phone>+61 3 9656 1266</phone>
      <fax>+61 3 9656 1420</fax>
      <email>Bev.McClur@petermac.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Paul Mitchell</name>
      <address>Austin Health, Studley Rd, Heidelberg, VIC 3084</address>
      <phone>+61 3 9496 3546</phone>
      <fax>+61 3 9496 3379</fax>
      <email>paul.mitchell@austin.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>